{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"EG000","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2"},{"deathsNumAffected":0,"deathsNumAtRisk":2,"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"EG001","otherNumAffected":2,"otherNumAtRisk":2,"seriousNumAffected":1,"seriousNumAtRisk":2,"title":"HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2"},{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"EG002","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2"},{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"EG003","otherNumAffected":6,"otherNumAtRisk":6,"seriousNumAffected":2,"seriousNumAtRisk":6,"title":"HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2"},{"deathsNumAffected":0,"deathsNumAtRisk":2,"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"EG004","otherNumAffected":2,"otherNumAtRisk":2,"seriousNumAffected":2,"seriousNumAtRisk":2,"title":"HPV-16 E6 mTCR PBL MTD + HD IL-2"},{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin\n\nFludarabine: Patients will receive Fludarabine 25 mg/m\\^2/day for 5 days.\n\nCyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days\n\nE6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)\n\nAldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).","id":"EG005","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"HPV-16 E6 mTCR PBL MTD + HD IL-2-Retreatment"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG002","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG003","numAffected":4,"numAtRisk":6,"numEvents":4},{"groupId":"EG004","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG005","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Hemoglobin"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"with Grade 3 or 4 neutrophils (ANC\\<1.0x10e9/L)::Blood","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Infection (documented clinically and microbiologically)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG002","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG003","numAffected":6,"numAtRisk":6,"numEvents":6},{"groupId":"EG004","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG005","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Lymphopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG002","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG003","numAffected":6,"numAtRisk":6,"numEvents":6},{"groupId":"EG004","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG005","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Neutrophils/granulocytes (ANC/AGC)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG002","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG003","numAffected":6,"numAtRisk":6,"numEvents":6},{"groupId":"EG004","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG005","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Platelets"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Bilirubin (hyperbilirubinemia)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"(fever of unknown origin without clinically or microbiologically documented infection)(ANC\\<1.0 x 10e9/L, fever\\>=38.5 degrees C)","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Febrile neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Psychosis (hallucinations/delusions)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Rash/desquamation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Hypotension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Creatinine"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":2,"numAtRisk":6,"numEvents":2},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Dyspnea (shortness of breath)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":2,"numAtRisk":6,"numEvents":2},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Supraventricular and nodal arrhythmia::Sinus tachycardia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Syncope (fainting)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Renal/Genitourinary - Other, Acute renal injury"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Pleural effusion (non-malignant)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Diarrhea"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Dyspnea (shortness of breath)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Hemorrhage, pulmonary/upper respiratory::Bronchopulmonary NOS"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Obstruction/stenosis of airway::Bronchus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Prolonged intubation after pulmonary resection (>24 hrs after surgery)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"with Grade 3 or 4 neutrophils (ANC \\<1.0 x 10e9/L)::Blood","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":2,"numAtRisk":6,"numEvents":2},{"groupId":"EG004","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Infection (documented clinically or microbiologically)"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"(fever of unknown origin without clinically or microbiologically documented infection)(ANC \\<1.0 x 10e9/L, fever \\>=38.5 degrees C)","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG003","numAffected":0,"numAtRisk":6,"numEvents":0},{"groupId":"EG004","numAffected":2,"numAtRisk":2,"numEvents":2},{"groupId":"EG005","numAffected":0,"numAtRisk":1,"numEvents":0}],"term":"Febrile neutropenia"}],"timeFrame":"19 months and 7 days"}